In HER2-positive breast cancer, this technology has investigated combinatorial immunotherapy strategies for CDK4/6 inhibitor resistance by elucidating rapidly evolving resistance mechanisms[254]. This evidence concerns the gene ERBB2 and breast carcinoma.